TB-500 and Thymosin Beta-4: What Published Research Has Examined

A sourced guide to the thymosin beta-4 literature and to TB-500, the short synthetic fragment it's often confused with: what each molecule is, the preclinical and clinical-trial work on Tβ4, and what's actually known about TB-500.

For laboratory research use only. 21+.

"TB-500" and "thymosin beta-4" are often used as if they were the same thing. They aren't, and the difference matters a great deal when you read the literature. Nearly all of the published biology concerns thymosin beta-4 (Tβ4), a naturally occurring 43-amino-acid protein. TB-500 is a much shorter synthetic peptide, and its own published record is small and comes mostly from doping-control laboratories.

This article separates the two. It covers what each molecule is, which experimental models researchers have used for Tβ4, what its registered clinical trials examined, and what's known specifically about TB-500. It describes what studies examined. It does not describe what either compound will do, and it gives no guidance on use outside the laboratory.

Two different molecules

Thymosin beta-4 (Tβ4)

Tβ4 belongs to the β-thymosins, a family of small, highly conserved peptides of about 5 kDa. They were originally thought to be thymic hormones. They were later identified as the main G-actin–sequestering peptides in cells, present at high concentrations in almost every cell type. β-thymosins bind single actin molecules in a 1:1 complex and act as an actin buffer: they prevent polymerization into filaments while keeping a pool of monomers available when the cell needs them (Huff et al., 2001; DOI: 10.1016/s1357-2725(00)00087-x). Tβ4 is also found outside cells, in blood plasma and wound fluid.

The synthetic version used in clinical trials is a copy of the full 43-amino-acid peptide (Guarnera et al., 2010).

TB-500

TB-500 is the name of a product, originally a veterinary preparation, whose key ingredient doping-control laboratories identified as the seven-residue sequence LKKTETQ with an acetylated N-terminus (Ac-LKKTETQ). That sequence corresponds to residues 17–23 of Tβ4, the region associated with actin binding (Ho et al., 2012; DOI: 10.1016/j.chroma.2012.09.043; Esposito et al., 2012; DOI: 10.1002/dta.1402).

So TB-500 is a fragment, about one-sixth the length of Tβ4. Findings about full-length Tβ4 can't be assumed to apply to the fragment. A 2024 study states it directly: "The biological effects of TB-500, however, have not been documented" (Rahaman et al., 2024; DOI: 10.1016/j.jchromb.2024.124033).

Research on full-length thymosin beta-4

Cell migration and dermal wound models

Early work at the US National Institutes of Health examined Tβ4 in wound models. In a 1999 study using a rat full-thickness wound model, researchers reported increased re-epithelialization compared with saline controls: 42% at day 4 and up to 61% at day 7. They also reported increased wound contraction, collagen deposition and angiogenesis. In a cell-migration assay, Tβ4 increased keratinocyte migration two- to three-fold over medium alone (Malinda et al., 1999; DOI: 10.1046/j.1523-1747.1999.00708.x).

A 2012 review from several of the same investigators summarizes skin wound-repair studies across normal, steroid-exposed, diabetic and aged rodent models (Treadwell et al., 2012; DOI: 10.1111/j.1749-6632.2012.06717.x).

Cardiac models

Two widely cited Nature papers from 2004 and 2007 made Tβ4 a subject of cardiovascular research:

  • In a 2004 study from UT Southwestern, Tβ4 formed a complex with PINCH and integrin-linked kinase (ILK), leading to activation of the survival kinase Akt. In mice after coronary artery ligation, the researchers reported increased early cardiomyocyte survival and improved cardiac function measures (Bock-Marquette et al., 2004; DOI: 10.1038/nature03000).
  • A 2007 study from UCL identified Tβ4 as essential for coronary vessel development in mice. It reported that Tβ4 stimulated outgrowth from quiescent adult epicardial explants, with differentiation into fibroblasts, smooth muscle cells and endothelial cells. The study also implicated the Tβ4 cleavage product Ac-SDKP (Smart et al., 2007; DOI: 10.1038/nature05383).

Neurological injury models

Researchers at Henry Ford Health System studied Tβ4 in a rat model of traumatic brain injury (controlled cortical impact). Compared with saline, they reported no difference in lesion volume. They did report reduced hippocampal cell loss, increased markers of angiogenesis, neurogenesis and oligodendrogenesis, and differences in sensorimotor and spatial-learning tests over 35 days (Xiong et al., 2011; DOI: 10.3171/2010.4.JNS10118).

Reviews of the Tβ4 literature

A 2012 review by researchers central to the field summarizes Tβ4 biology in skin, eye, heart and brain models, and the rationale for clinical trials (Goldstein et al., 2012; DOI: 10.1517/14712598.2012.634793). A 2010 review from the company developing Tβ4 describes its proposed activities and the clinical programs underway at the time (Crockford et al., 2010; DOI: 10.1111/j.1749-6632.2010.05492.x). Readers should note that commercial affiliation.

Registered clinical trials of thymosin beta-4

Unlike most research peptides, full-length Tβ4 has been tested in registered, randomized, placebo-controlled Phase 2 trials, all using topical formulations (eye drops or a topical gel). These were formal, regulated clinical studies. They are described here as research history, not as evidence about any research-grade product.

Venous stasis ulcers. A double-blind, placebo-controlled Phase 2 study at eight European sites, comparing several concentrations of a topical formulation, randomized 73 participants to topical Tβ4 or placebo. The authors reported a safety profile comparable to placebo. Efficacy findings were described as suggestive rather than conclusive (Guarnera et al., 2010; DOI: 10.1111/j.1749-6632.2010.05490.x).

Dry eye. Two Phase 2 trials tested a Tβ4 ophthalmic solution:

That mixed primary-endpoint result is worth noticing. Even the best-controlled Tβ4 research doesn't give a simple story.

Research on TB-500 itself

The published work specifically on TB-500 (Ac-LKKTETQ) is mainly analytical:

  • Detection in horses. The Hong Kong Jockey Club's racing laboratory developed an LC-MS method to detect Ac-LKKTETQ and its metabolites in equine urine and plasma, prompted by concern about its misuse in equine sport (Ho et al., 2012).
  • Identification and synthesis. The Ghent doping-control lab identified Ac-LKKTETQ in a TB-500 product by high-resolution mass spectrometry, synthesized it as a reference standard, and proposed a detection strategy for plasma and urine (Esposito et al., 2012).
  • Metabolism and cell activity. A 2024 study from the Korea Institute of Science and Technology's Doping Control Center quantified TB-500 and its metabolites in vitro and in rats. It identified Ac-LK as the main early metabolite and Ac-LKK as a longer-lasting one. In fibroblast wound-closure (scratch) assays, only the metabolite Ac-LKKTE showed significant activity versus control. The authors suggest that activity previously attributed to TB-500 may come from this metabolite rather than the parent peptide (Rahaman et al., 2024).

Recent clinical reviews are cautious. A 2026 review for orthopaedic physicians notes that Tβ4 and TB-500 promoted angiogenesis and tissue repair in preclinical models, but "human orthopaedic data are lacking" (Mayfield et al., 2026; DOI: 10.1177/03635465251357593). Another lists TB-500 among unapproved peptides that "lack established human safety profiles" (Moiz et al., 2026).

Open questions in the literature

  1. Fragment vs. full-length. How much of Tβ4's reported biology, if any, is reproduced by the seven-residue fragment?
  2. Parent vs. metabolite. The 2024 data raise the possibility that fragment activity comes from metabolites.
  3. Cell migration in other contexts. Reviews of β-thymosins discuss their roles in cell migration in both normal tissue and tumor metastasis (Sribenja et al., 2013; DOI: 10.3109/07357907.2012.756111). That's an active research question for any molecule studied for pro-migratory or angiogenic activity.
  4. Human evidence for TB-500. None of the Tβ4 clinical trials tested TB-500.

Why identity testing matters here more than usual

Because "TB-500" and "thymosin beta-4" name different molecules of very different sizes, mass spectrometry is the single most useful check on any vial. The observed mass immediately tells you whether the material is the seven-residue acetylated fragment or the 43-residue protein. A purity number alone can't.

Seratide supplies TB-500 as lyophilized powder in lot-numbered vials, for laboratory research use only. Each lot's record, with HPLC purity, LC-MS identity and endotoxin, is on our Lot lookup page. Today these are clearly labeled layout samples that show the format, not measurements. Issued laboratory reports replace them as lots are analyzed. You can browse the rest of the catalog on the research peptides shelf.

Sources

All sources below were opened and checked against their PubMed records while drafting. The full title of each paper is on its PubMed page.

  1. Huff T, et al. Int J Biochem Cell Biol. 2001;33(3):205-20. PubMed: https://pubmed.ncbi.nlm.nih.gov/11311852/ · DOI: https://doi.org/10.1016/s1357-2725(00)00087-x
  2. Ho EN, et al. J Chromatogr A. 2012;1265:57-69. PubMed: https://pubmed.ncbi.nlm.nih.gov/23084823/ · DOI: https://doi.org/10.1016/j.chroma.2012.09.043
  3. Esposito S, et al. Drug Test Anal. 2012;4(9):733-8. PubMed: https://pubmed.ncbi.nlm.nih.gov/22962027/ · DOI: https://doi.org/10.1002/dta.1402
  4. Rahaman KA, et al. J Chromatogr B. 2024;1235:124033. PubMed: https://pubmed.ncbi.nlm.nih.gov/38382158/ · DOI: https://doi.org/10.1016/j.jchromb.2024.124033
  5. Malinda KM, et al. J Invest Dermatol. 1999;113(3):364-8. PubMed: https://pubmed.ncbi.nlm.nih.gov/10469335/ · DOI: https://doi.org/10.1046/j.1523-1747.1999.00708.x
  6. Treadwell T, et al. Ann N Y Acad Sci. 2012;1270:37-44. PubMed: https://pubmed.ncbi.nlm.nih.gov/23050815/ · DOI: https://doi.org/10.1111/j.1749-6632.2012.06717.x
  7. Bock-Marquette I, et al. Nature. 2004;432(7016):466-72. PubMed: https://pubmed.ncbi.nlm.nih.gov/15565145/ · DOI: https://doi.org/10.1038/nature03000
  8. Smart N, et al. Nature. 2007;445(7124):177-82. PubMed: https://pubmed.ncbi.nlm.nih.gov/17108969/ · DOI: https://doi.org/10.1038/nature05383
  9. Xiong Y, et al. J Neurosurg. 2011;114(1):102-15. PubMed: https://pubmed.ncbi.nlm.nih.gov/20486893/ · DOI: https://doi.org/10.3171/2010.4.JNS10118
  10. Goldstein AL, et al. Expert Opin Biol Ther. 2012;12(1):37-51. PubMed: https://pubmed.ncbi.nlm.nih.gov/22074294/ · DOI: https://doi.org/10.1517/14712598.2012.634793
  11. Crockford D, et al. Ann N Y Acad Sci. 2010;1194:179-89. PubMed: https://pubmed.ncbi.nlm.nih.gov/20536467/ · DOI: https://doi.org/10.1111/j.1749-6632.2010.05492.x
  12. Guarnera G, et al. Ann N Y Acad Sci. 2010;1194:207-12. PubMed: https://pubmed.ncbi.nlm.nih.gov/20536470/ · DOI: https://doi.org/10.1111/j.1749-6632.2010.05490.x
  13. Sosne G, Dunn SP, Kim C. Cornea. 2015;34(5):491-6. PubMed: https://pubmed.ncbi.nlm.nih.gov/25826322/ · DOI: https://doi.org/10.1097/ICO.0000000000000379
  14. Sosne G, Ousler GW. Clin Ophthalmol. 2015;9:877-84. PubMed: https://pubmed.ncbi.nlm.nih.gov/26056426/ · DOI: https://doi.org/10.2147/OPTH.S80954
  15. Mayfield CK, et al. Am J Sports Med. 2026;54(1):223-229. PubMed: https://pubmed.ncbi.nlm.nih.gov/41476424/ · DOI: https://doi.org/10.1177/03635465251357593
  16. Moiz A, et al. Mo Med. 2026;123(4):337-343. PubMed: https://pubmed.ncbi.nlm.nih.gov/42757290/ (no DOI listed in PubMed)
  17. Sribenja S, et al. Cancer Invest. 2013;31(2):103-10. PubMed: https://pubmed.ncbi.nlm.nih.gov/23320791/ · DOI: https://doi.org/10.3109/07357907.2012.756111

For laboratory research use only.

More from the library